Melanoma Prognostic Model Using Tissue Microarrays and Genetic Algorithms

PURPOSE: As a result of the questionable risk-to-benefit ratio of adjuvant therapies, stage II melanoma is currently managed by observation because available clinicopathologic parameters cannot identify the 20% to 60% of such patients likely to develop metastatic disease. Here, we propose a multimar...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Gould Rothberg, Bonnie E., Berger, Aaron J., Molinaro, Annette M., Subtil, Antonio, Krauthammer, Michael O., Camp, Robert L., Bradley, William R., Ariyan, Stephan, Kluger, Harriet M., Rimm, David L.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2009
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2792999/
https://ncbi.nlm.nih.gov/pubmed/19884546
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.22.8239
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados